This gallery contains 1 photo.
At least once a week I get drawn into a discussion about how virtual a medtech company can be – from its early stages right through to regulatory approval and even market launch. So, this post explores a few opportunities … Continue reading
This gallery contains 1 photo.
“Mighty oaks from little acorns grow” As medtech specialists we spend our time working in a tough, competitive environment. Rewards are not distributed equally – the lions share goes to the winners, and the rest to everyone else. Are there … Continue reading
This gallery contains 3 photos.
Corporate venture capital “is the investment of corporate funds directly in external start-up companies” (Wikipedia). As a medtech entrepreneur raising funds, you should know about them. They are an extremely valuable source of VC funding for your company. But they … Continue reading
This gallery contains 4 photos.
Many investors are specialists. Indeed, specialism in something is usually the way to excel at whatever is your choosing. But can it lead to challenges (e.g. tunnel vision), and is there a way to overcome the specialist’s curse? I’ve spent … Continue reading
This gallery contains 1 photo.
Last week I added Teva Pharmaceutical Industries (Symbol: TEVA) to my stock portfolio, at a price of $44.40. It’s not medtech, but it’s still within my chosen niche area of healthcare, and offers many of the traits I look for … Continue reading
This gallery contains 2 photos.
What do angel investors look for when considering investment opportunities? And what separates the success stories from the also-rans (or even crashes)? Recently I had the chance to discuss this with a successful angel investor and financier, Peter Mountford. Over … Continue reading
Last month’s article, Lessons from Medtech, looked at certain investment characteristics of invasive medtech companies and considered how these might be attractive to other life science and healthcare companies, particularly biotech. Chief amongst these was building revenues and profits, early … Continue reading
In his 2004 Chairman’s Letter at Berkshire Hathaway, Warren Buffet offered sound advice to those trying to find the best time to invest in equities: “be fearful when others are greedy and greedy when others are fearful”….But is going against the grain also a winning strategy for private equity investors in high-risk biotech ventures?
Continue reading
Many folks within pharma lament the current challenges and look back to a gilded era when blockbusters provided rivers of cash flow and supported growth based activities – both R&D and marketing. And yet, could this present biotech’s greatest opportunity … Continue reading
Last week witnessed an interesting M&A deal between SuperGen and Astex. Here, we look at investor returns and wonder what could be in store for the enlarged company? Supergen (SUPG) is a NASDAQ listed biotech with a market cap of … Continue reading
